Urogen Pharma, Inc.
$2.3M 7,857 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Albireo Pharma, Inc.
Albireo Pharma, Inc. reported $2,311,859.76 across General Payments, Research, and Ownership to 371 physicians and teaching hospitals across 879 transactions.
- $2.3M Top quartile payer
- All-tracks total
- 879 Above-median volume
- Transactions
- 371 Above-median reach
- Recipients
- −$301.5K
- General Payments vs PY2023
Albireo Pharma, Inc. reported $2,311,859.76 across all CMS Open Payments tracks (General + Research + Ownership) to 371 physicians and teaching hospitals in Program Year 2024 - ranking #420 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $317,243.65, averaging $6.2K per recipient.
How Albireo Pharma, Inc.'s $2.3M all-tracks total breaks down
Albireo Pharma, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
34/100
Total payments
F
31/100
Transaction volume
F
16/100
Physician reach
F
13/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer albireo-pharma-inc Albireo Pharma, Inc.
$2.3M · #420/1,925 · 0.0% industry · PY2024
- TOT $2.3M
- RANK #420
- SHARE 0.0%
- TXN 879
- RCP 371
- CAT 6
- GEN $317.2K
- ΔGEN −$301.5K
- TOP1 35.4%
- PY 2024
Volume peers
Nearest volume peer: Urogen Pharma, Inc. ($2.3M)
Albireo Pharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Albireo Pharma, Inc.'s CMS-reported General Payments decreased by $301.5K (−48.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALBIREO PHARMA, INC.PY2023: ALBIREO PHARMA, INC.PY2024: ALBIREO PHARMA, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $618,781.14
- PY2024
- $317,243.65
What the Data Shows for Albireo Pharma, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Albireo Pharma, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 6-category general-payment breakdown below at $120.8K (38.1% of General Payments, 8 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Albireo Pharma, Inc. made 6 types of general payments. "Consulting Fee" is the largest category at $120.8K, 38.1% of General Payments.
Albireo Pharma, Inc. reports 6 general-payment categories - the top three are Consulting Fee (38.1%), Education (35.4%), and Travel and Lodging (22.6%). The remaining 3 categories make up 3.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Albireo Pharma, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $120.8K | 8 | 38.1% |
| Education | $112.4K | 2 | 35.4% |
| Travel and Lodging | $71.6K | 38 | 22.6% |
| Food and Beverage | $9.2K | 321 | 2.9% |
| Honoraria | $2.5K | 1 | 0.8% |
| Compensation for Services Other Than Consulting | $744.23 | 1 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $233,153.50 (73.5%) of $317,243.65 in this company's General Payments records across 227 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Albireo Pharma, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Emory University Hospital
$112,359.00 across 2 reported transactions
- 2
William R Treem
$46,575.00 across 1 reported transactions
- 3
Naga P Chalasani
$38,686.00 across 2 reported transactions
- 4
Karen F Murray
$19,763.50 across 3 reported transactions
- 5
Maureen M Jonas
$15,770.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Albireo Pharma, Inc. ranks #420 of 1,925 by total payments (top 22% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #807 of 1,838 by HHI (top 44% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Pfizer International LLC : $197.5K total payments, HHI 1747
- NextStep Arthropedix, LLC : $125.7K total payments, HHI 1747
- Greiner Bio-One North America, Inc. : $11.6K total payments, HHI 1746
- CashFlow Solutions, LLC : $89.2K total payments, HHI 1745
- Acumed LLC : $3.4M total payments, HHI 1742
- Thermo Fisher Scientific Asheville LLC : $2.2K total payments, HHI 1739
- Albireo Pharma, Inc. (this company) : $317.2K total payments, HHI 1739
- Puma Biotechnology, Inc. : $396.8K total payments, HHI 1733
- Pulse Biosciences, Inc. : $534.8K total payments, HHI 1730
- SS White Burs, Inc. : $65.6K total payments, HHI 1718
- Maquet Cardiovascular L.L.C. : $188.3K total payments, HHI 1714
- GS Solutions, Inc. : $38.7K total payments, HHI 1706
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Albireo Pharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Albireo Pharma, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Albireo Pharma, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Checkpoint Surgical, Inc
$2.3M 887 recipients
Compare payment profiles
Ethicon Endo-Surgery Inc.
$2.3M 150 recipients
Compare payment profiles
Aimmune Therapeutics, Inc.
$2.3M 32,592 recipients
Compare payment profiles
Recordati_rare_diseases_inc.
$2.3M 5,392 recipients
Compare payment profiles
Ceribell, Inc.
$2.3M 1,173 recipients
Compare payment profiles
Put this to use
Albireo Pharma, Inc. ranks #420 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Albireo Pharma, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Albireo Pharma, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.